O’Melveny & Myers LLP represented Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) in its proposed public offering. The company, which develops medicines related to cancer treatment, plans to use the proceeds for research and development and general corporate purposes.

The O’Melveny team was led by partners Jennifer DePalma and Sam Zucker, senior counsel Stanton Lovenworth, and counsel Ruchun Ji.



Related Posts:

Leave a Reply